Skip to content

Fatmax Exercise in Menstrual Phases: Effects on Fat Metabolism & Body Composition in NWO Women

Effects of a Fatmax Exercise Intervention During Different Menstrual Cycle Phases on Fat Metabolism and Body Composition in Normal Weight Obese Women

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06961734
Enrollment
48
Registered
2025-05-08
Start date
2023-02-23
Completion date
2023-12-31
Last updated
2025-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fat Metabolism

Keywords

aerobic exercise, menstrual cycle phase, normal weight obesity, lipid metabolism

Brief summary

Effects of a Fatmax exercise intervention during different menstrual phases on fat metabolism and body composition in NWO women

Detailed description

This is a randomized clinical trial of single-blind with 3 arms (control group , follicular group and luteal group), in which a pre-treatment-posttest design has been used.

Interventions

BEHAVIORALfollicular group

Exercised at Fatmax intensity four times per week and plus three additional exercise during the late follicular phase of each cycle.

BEHAVIORALluteal group

Exercised at Fatmax intensity four times per week and plus three additional exercise during the mid- luteal phase of each cycle.

BEHAVIORALControl group

Exercised at Fatmax intensity four times per week.

Sponsors

Beijing Sport University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* Criteria: Inclusion Criteria: * Female, aged between 18 and 30 years old; * BMI between 18.5 and 24.9 kg/m2 with a BF% \> 30% (normal weight obesity determination criteria); * Regular menstrual cycles for at least 3 months; * No use of oral contraceptives for at least 6 months before the experiment; * Non-smoker and non-alcohol abuser.

Exclusion criteria

* The presence of CVD; * A diagnosis of cancer, pulmonary diseases, or other conditions that prevent participation in exercise; * The use of medications affecting body composition or metabolism.

Design outcomes

Primary

MeasureTime frameDescription
Lipid profile8 weeksThe changes of high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, total cholesterol, and triglyceride before and after intervention.
Body Fat Mass8 weeksBody fat mass (kg) will be assessed using dual-energy X-ray absorptiometry (DXA) scans. The change of body fat mass before and after intervention.
Percentage of Body Fat8 weeksThe change of percentage of body fat before and after intervention.

Secondary

MeasureTime frameDescription
Body Mass Index (BMI)8 weeksChanges in Body mass index before and after Intervention. Body mass index is calculated from the formula, Weight (kg) / Height2 (m2), its unit is kg/m2.
Waist Circumference8 weeksThe change of waist circumference before and after intervention.
Hip Circumference8 weeksThe change of hip circumference before and after intervention.
Apolipoprotein A-I (g/L)8 weeksThe change in apolipoprotein A-I levels before and after the intervention.
Apolipoprotein B (g/L)8 weeksThe change in apolipoprotein B levels before and after the intervention.
Maximal Oxygen uptake (VO2max)8 weeksChanges in Maximal Oxygen uptake before and after Intervention.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026